Redeye provides a research note on Faron Pharmaceuticals following the outcome of the company’s rece...
Better Collective has released preliminary results for Q4 which were stronger than expected, support...
Redeye continues to be positive to Bredband2 following a Q4 report in line with our estimates, posti...
Redeye comments on Göran Forsberg leaving as CEO with Damian Marron from the board taking the role ...
ASTar was awarded the tender at Cliniques Universitaires Saint-Luc in Brussels.
Redeye comments on Tessin’s Q4 results, which were softer than expected.
EBIT SEK -28m vs. ABG SEK -25m — lower volumes Q1 likely better — no maintenance Conference call at ...
Fiskars Q4 adjusted EBIT of EUR 42.9m came 2% above Modular Finance consensus expectations.
Sales SEK 630m, -15% vs. ABGSCe EBIT of SEK 51m, -5% vs.
Redeye comments on I-Tech’s Q4 figures that significantly beat our estimates across the board, prima...
Redeye’s first take on the Q4 report this morning. Again, there were considerable changes in sales i...
Redeye is encouraged to see organic growth in the quarter after a relatively weak performance during...
Redeye continues to see a compelling long-term investment case.
Redeye updates its estimates and valuation following Vitec releasing its Q4 2024 report.
Q4'24 results due 11 February '25e-'26e adj. EBIT revised by 0.
